Andrew D Cherniack
Group Leader
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (73)
Exon 20 insertions of HER2, encoded by erb-b2 receptor tyrosine kinase 2 ( ERBB2 ), and other activating HER2 mutations occur in 2% to 4% of lung adenocarcinomas, but there are only limited therapeutic options available for these patients. Sevabertinib (BAY 2927088) is a potent and reversible dual EGFR–HER2 inhibitor that is selective with respect to wild-type EGFR. In this study, we report the preclinical activity of sevabertinib in lung cancer models harboring alterations of HER2, including exon 20 insertions, point mutations, and amplification of wild-type ERBB2 . We furthermore demonstrate the activity of sevabertinib in a cancer cell line dependent on a fusion of neuregulin-1, a ligand for the HER2 family member and heterodimerization partner, HER3. Finally, we report patient responses to sevabertinib from a phase 1/2 clinical trial, indicating potential benefit for patients with HER2-mutant lung cancer. Significance: Additional therapeutic options are needed for patients with lung cancer with HER2 activating mutations, including exon 20 insertions. Sevabertinib shows activity against ERBB2 -encoded HER2 exon 20 insertions in preclinical models of lung cancer, corroborated by early data from a phase 1/2 clinical trial.
Year:
2026
Ovarian cancers and microsatellite stable (MSS) colorectal cancers are insensitive to anti–programmed cell death 1 (PD-1) immunotherapy, and new immunotherapeutic approaches are needed. Preclinical data suggest a relationship between immunotherapy resistance and elevated angiopoietin 2 levels. We performed a phase I dose escalation study of pembrolizumab and the angiopoietin 1/2 inhibitor trebananib (NCT03239145). This multicenter trial enrolled patients with metastatic ovarian cancer or MSS colorectal cancer. Trebananib was administered intravenously weekly for 12 weeks with 200 mg intravenous pembrolizumab every 3 weeks. The toxicity profile of this combination was manageable, and the protocol-defined highest dose level (trebananib 30 mg/kg weekly plus pembrolizumab 200 mg every 3 weeks) was declared the maximum tolerated dose. The objective response rate for all patients was 7.3% (90% confidence interval, 2.5%–15.9%). Three patients with MSS colorectal cancer had durable responses for ≥3 years. One responding patient’s colorectal cancer harbored a POLE mutation. The other two responding patients had left-sided colorectal cancers, with no baseline liver metastases, and genomic analysis revealed that they both had KRAS wild-type, ERBB2-amplified tumors. After development of acquired resistance, biopsy of one patient’s KRAS wild-type ERBB2-amplified tumor showed a substantial decline in tumor-associated T cells and an increase in immunosuppressive intratumoral macrophages. Future studies are needed to carefully assess whether clinicogenomic features, such as lack of liver metastases, ERBB2 amplification, and left-sided tumors, can predict increased sensitivity to PD-1 immunotherapy combinations.
Year:
2025
Supplementary Figure 21. (A) Intratumoral, (B) tumor-stroma interface, and (C) total CD8+ PD1+ T cells in ATMMUT and ATMWT NSCLCs. (D) Intratumoral, (E) tumor-stroma interface, and (F) total FOXP3+ immune cells in ATMMUT and ATMWT NSCLCs.
Year:
2025
Supplementary Figure 14. (A) Objective response rate, (B) progression-free survival, and (C) overall survival to PD-(L)1 immune checkpoint blockade monotherapy among patients with advanced/metastatic PD-L1 negative (
Year:
2025
Supplementary Figure 7. (A) Histograms showing the distribution of deleterious class I and class II ATM mutations with lost or intact ATM protein expression by IHC. (B) Histograms showing the distribution of deleterious missense, nonsense, splice site, and insertion/deletion mutations with lost or intact ATM protein expression by IHC. (C) proportion of NSCLCs with predicted benign and predicted pathogenic ATM missense mutations with lost and intact ATM expression by IHC.
Year:
2025
Supplementary Figure 29. Box plot showing immune cell subsets significantly enriched among ATMMUT versus ATMWT NSCLC as assessed by deconvoluting bulky RNAseq data from the TCGA-NSCLC dataset. Non-significant results are not shown.
Year:
2025
Supplementary Figure 19. (A) Objective response rate, (B) progression-free survival, and (C) overall survival to PD-(L)1 immune checkpoint blockade monotherapy among patients with ATMMUT NSCLC, according to KEAP1 mutation. (D) Objective response rate, (E) progression-free survival, and (F) overall survival to PD-(L)1 immune checkpoint blockade in combination with platinum doublet chemotherapy among patients with ATMMUT NSCLC, according to KEAP1 mutation status
Year:
2025
Supplementary Figure 10. (A) Progression-free and (B) overall survival among all patients with stage III NSCLC according to ATM mutation status. (C) Progression-free and (D) overall survival among patients with stage III NSCLC who received concurrent chemoradiotherapy followed by durvalumab maintenance according to ATM mutation status.
Year:
2025
Supplementary Figure 5. (A) Median distance of each missense mutation from the closest intron start. (B) Median distance of each missense mutation from the closest intron end. (C) Proportion of cases with ATM loss and ATM intact expression by IHC in NSCLC samples with ATM mutation and ATM loss-of-heterozygosity (LOH).
Year:
2025
Supplementary Figure 17. (A) Objective response rate, (B) progression-free survival, and (C) overall survival to PD-(L)1 inhibition among patients with advanced/metastatic NSCLC, according to ATM expression by immunohistochemistry.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (36)
Alessandro Di Federico
University of Bologna
Mark Awad
Chief, Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
Hersh Gupta
Dana-Farber Cancer Institute
Annacarolina da Silva
Assistant Professor of Pathology and Laboratory Medicine
Weill Cornell Medical College
Livio Trusolino
Full Professor, University of Torino School of Medicine
Candiolo Cancer Institute, FPO-IRCCS
Paolo Grassi
Fondazione IRCCS Istituto Nazionale dei Tumori
Shahab Sarmashghi
Broad Institute
Emma Welsh
Dana-Farber Cancer Institute
Kimmie Ng
Associate Professor of Medicine, Harvard Medical School
Dana-Farber Cancer Institute
Mizuki Nishino
King’s College London
Ryan Corces
Assistant Investigator
Gladstone Institutes
Federica Piccioni
Group Leader
Broad Institute
Nancy Lin
Associate Professor of Medicine
Dana-Farber Cancer Institute
Richard Schilsky
Chief Medical Officer
-
Howard Y. Chang
Stanford University School of Medicine
Jeffrey Clark
Associate Professor
Harvard University
Daniel Gomez
Chair, Radiation Oncology
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health
Srivatsan Raghavan
Assistant Professor
Dana-Farber Cancer Institute
Bruno Bockorny
Beth Israel Deaconess Medical Center
Christina Curtis
Professor of Medicine & Genetics
Stanford University
Scott Rodig
Professor of Pathology
Beth Israel Deaconess Medical Center
Andrea Bertotti
Candiolo Cancer Institute
Neal Lindeman
Vice Chair, Molecular Pathology and Laboratory Medicine
Weill Cornell Medicine
Andrew McPherson
Assistant Attending
Sloan Kettering Institute
Brittany Bychkovsky
Assistant Professor of Medicine
Dana-Farber Cancer Institute
Elizabeth Cohen
Dana-Farber Cancer Institute
Keith Ligon
Chief of Neuropathology/Principal Investigator
Dana-Farber Cancer Institute
Steven Corsello
Stanford University
Sheheryar Kabraji
Associate Professor
Roswell Park Comprehensive Cancer Center
Chen Yuan
Assistant Professor
Cedars-Sinai Medical Center
Michael Rosenthal
Brigham and Women's Hospital
Filipa Lynce
Dana-Farber Cancer Institute
William Greenleaf
Professor
Stanford University
Eric Winer
Director
Yale University
PETER W LAIRD
Professor, Peter and Emajean Cook Endowed Chair in Epigenetics
Van Andel Institute
Matthew Meyerson
Director, Center for Cancer Genomics
Dana-Farber Cancer Institute
Make your next move.
Prepare your application
Review drafts before you send them.